Earnings summaries and quarterly performance for Penumbra.
Executive leadership at Penumbra.
Board of directors at Penumbra.
Research analysts who have asked questions during Penumbra earnings calls.
RN
Richard Newitter
Truist Securities
4 questions for PEN
Also covers: AXNX, DXCM, GKOS +18 more
RM
Robert Marcus
JPMorgan Chase & Co.
4 questions for PEN
Also covers: ABT, BAX, BDX +21 more
MK
Macauley Kilbane
William Blair & Company
3 questions for PEN
Also covers: CBLL, CVRX, GKOS +4 more
MS
Michael Sarcone
Jefferies
3 questions for PEN
Also covers: ALC, AXGN, CTSO +11 more
PC
Pito Chickering
Deutsche Bank
3 questions for PEN
Also covers: ACHC, AHCO, AVAH +18 more
Ryan Zimmerman
BTIG
3 questions for PEN
Also covers: ALC, GEHC, GKOS +23 more
Joanne Wuensch
Citigroup Inc.
2 questions for PEN
Also covers: ABT, BAX, BDX +18 more
LH
Lei Huang
Wells Fargo
2 questions for PEN
Also covers: NVCR, RXST, SOLV
Michael Kratky
Leerink Partners
2 questions for PEN
Also covers: AXGN, BBNX, DXCM +6 more
Samantha Kurtz
Piper Sandler Companies
2 questions for PEN
Also covers: SYK
Travis Steed
Bank of America
2 questions for PEN
Also covers: ABT, AXNX, BAX +19 more
William Plovanic
Canaccord Genuity
2 questions for PEN
Also covers: ATRC, CBLL, CVRX +9 more
Bill Plovanic
Canaccord Genuity
1 question for PEN
Also covers: ANGO, AORT, CBLL +7 more
BV
Brandon Vazquez
William Blair & Company, L.L.C.
1 question for PEN
Also covers: ALGN, CBLL, CVRX +17 more
Chris Pasquale
Nephron Research LLC
1 question for PEN
Also covers: ALC, AXGN, BSX +7 more
Christopher Pasquale
Nephron Research
1 question for PEN
Also covers: ALC, AXGN, BSX +12 more
DR
David Rescott
Baird
1 question for PEN
Also covers: HAE, INSP, IRTC +7 more
Kallum Titchmarsh
Morgan Stanley
1 question for PEN
Also covers: ATEC, AXNX, EMBC +5 more
LB
Larry Biegelsen
Wells Fargo & Company
1 question for PEN
Also covers: ABT, ALC, AXNX +24 more
LB
Lawrence Biegelsen
Wells Fargo
1 question for PEN
Also covers: ABT, ALC, BAX +16 more
MB
Mathew Blackman
Stifel
1 question for PEN
Also covers: AHCO, ATEC, BBNX +7 more
MO
Matthew O'Brien
Piper Sandler & Co.
1 question for PEN
Also covers: APYX, ATEC, ATRC +18 more
Michael Matson
Needham & Company
1 question for PEN
Also covers: AORT, ATRC, CNMD +22 more
SM
Samantha Munoz
Piper Sandler Companies
1 question for PEN
Also covers: ATEC, CVRX, TELA +1 more
SS
Shagun Singh Chadha
RBC Capital Markets
1 question for PEN
Also covers: AXNX, DXCM, GMED +11 more
Recent press releases and 8-K filings for PEN.
Penumbra Announces Acquisition by Boston Scientific and Preliminary Q4 and FY 2025 Results
PEN
M&A
Earnings
Guidance Update
- Penumbra, Inc. is being acquired by Boston Scientific Corporation in a cash and stock transaction valued at $374 per share, reflecting an enterprise value of approximately $14.5 billion.
- The transaction consideration will be approximately 73% cash and 27% Boston Scientific common stock, with Penumbra stockholders having the right to elect their preferred form of consideration.
- For the fourth quarter of 2025, Penumbra reported preliminary revenue between $383.0 million and $384.8 million, representing growth of approximately 21.4% to 22.0% compared to Q4 2024.
- For the full year 2025, preliminary revenue was between $1,401.3 million and $1,403.1 million, an increase of approximately 17.3% to 17.5% over the prior fiscal year.
- Preliminary Q4 2025 gross margin was 67.9% to 68.1%, with income from operations ranging from $56.9 million to $60.4 million.
Jan 15, 2026, 12:15 PM
Penumbra Provides Preliminary Q4 and Full Year 2025 Financial Results
PEN
Earnings
Guidance Update
- Penumbra, Inc. announced preliminary fourth quarter 2025 revenue between $383.0 million and $384.8 million, reflecting growth of approximately 21.4% to 22.0% compared to the fourth quarter of 2024.
- For the full year 2025, preliminary revenue is estimated to be between $1,401.3 million and $1,403.1 million, representing growth of approximately 17.3% to 17.5% compared to the full year 2024.
- The company reported preliminary gross margin of 67.9% to 68.1% for the fourth quarter 2025 and 67.1% for the full year 2025.
- Preliminary income from operations for the fourth quarter 2025 was $56.9 million to $60.4 million, with an operating margin of 14.8% to 15.7%.
Jan 15, 2026, 12:00 PM
Penumbra Highlights Strong Clinical Data, Embolization Growth, and Manufacturing Expansion
PEN
Product Launch
New Projects/Investments
Revenue Acceleration/Inflection
- Penumbra is expanding its manufacturing capabilities with a new facility in Costa Rica scheduled to open in mid to late 2027.
- The company's Thunderbolt computer-assisted vacuum thrombectomy (CAVT) product is currently under FDA submission, with the company having addressed follow-up questions.
- The STORM-PE trial demonstrated statistically significant positive outcomes for Penumbra's CAVT arm in pulmonary embolism treatment, including a reduction in RV/LV ratio and strong safety, with procedure times as low as 25 minutes.
- The embolization business, particularly for MMA (middle meningeal artery) embolization with the Swift Coil, has become a significant growth driver, achieving over 100% growth in recent quarters.
- Penumbra aims to exit 2026 with 70%+ margins.
Jan 12, 2026, 11:45 PM
Penumbra Highlights Manufacturing Expansion, Product Performance, and Margin Targets
PEN
New Projects/Investments
Revenue Acceleration/Inflection
Guidance Update
- Penumbra is expanding its manufacturing capabilities with a new 330,000 sq ft facility in Costa Rica slated to open in mid-to-late 2027, complementing its existing California operations.
- The company's thrombectomy business is seeing strong results, particularly from the STORM-PE trial for pulmonary embolism, which showed statistically significant improvements and excellent safety, while its neuro thrombectomy product, Thunderbolt, is currently under FDA submission.
- Penumbra's embolization business is a significant growth driver, with its coil business achieving over 100% growth in recent quarters, boosted by a new coil launch and the emerging opportunity in Middle Meningeal Artery (MMA) embolization.
- The company is committed to achieving 70%+ margins by the end of 2026, driven by operational efficiencies and strategic market adjustments.
Jan 12, 2026, 11:45 PM
Penumbra, Inc. Presents Company Overview, Manufacturing Expansion, and Clinical Trial Results at J.P. Morgan Healthcare Conference
PEN
New Projects/Investments
- Penumbra, Inc. is headquartered in Alameda, has approximately 4,500 employees, and its products are available in 100+ markets.
- The company is expanding its manufacturing capabilities with a new 330,000 square foot facility in Costa Rica that is due to open in mid-2027.
- Penumbra highlighted a total annual U.S. market opportunity of over 1,250,000 patients for its thrombectomy products and market opportunities including 175,000 peripheral procedures and 140,000 MMAe patients for embolization.
- The STORM-PE RCT demonstrated that the CAVT arm achieved a significantly greater reduction in right heart strain (29.7% relative reduction) compared to the AC arm, with a comparable safety profile and 100% technical success.
Jan 12, 2026, 11:45 PM
Penumbra Discusses Growth Drivers, Manufacturing Expansion, and Margin Outlook at J.P. Morgan Healthcare Conference
PEN
New Projects/Investments
Revenue Acceleration/Inflection
Guidance Update
- Penumbra is expanding its manufacturing capabilities with a new 330,000 sq ft facility in Costa Rica scheduled to open in mid to late 2027, which is expected to support the production of more cost-effective products.
- The company highlights significant growth in both its thrombectomy and embolization businesses, with the latter seeing over 100% growth in recent quarters, particularly from the Middle Meningeal Artery (MMA) opportunity.
- The Thunderbolt neuro product is currently 9 months into its FDA submission process, with the company addressing follow-up questions.
- Penumbra is committed to achieving over 70% margins by the end of 2026 and anticipates that China will no longer be a growth headwind in 2026.
Jan 12, 2026, 11:45 PM
Penumbra Discusses Strong Q3 Performance, New Products, and Clinical Trial Results
PEN
Product Launch
Revenue Acceleration/Inflection
New Projects/Investments
- Penumbra reported strong Q3 performance in its MO and access business, driven by the launch of Ruby XL and the expansion of its sales force.
- The company highlighted a significant growth opportunity in MMA embolization on the neuro side, with a potential $1 billion opportunity for this new procedure.
- Results from the STORM-PE trial demonstrated that mechanical thrombectomy with CAVT is superior to anticoagulation for pulmonary embolism treatment, showing high safety and fast procedure times (25-minute device time, 56-minute procedure time), which is expected to drive increased market penetration.
- Penumbra introduced 3.0, an updated product with both software and hardware changes, offering faster operation and less blood loss compared to its predecessor.
- The FDA review process for the Thunderbolt product is described as thorough but routine, with the company addressing clarifying questions.
Dec 3, 2025, 1:00 PM
Penumbra Highlights Strong Q3 Performance, New Product Launches, and Positive Clinical Data
PEN
Product Launch
Revenue Acceleration/Inflection
New Projects/Investments
- Penumbra reported strong performance in its MO and access business in Q3, driven by a new sales force and the successful launch of Ruby XL, a large vessel coil for peripheral vascular embolization.
- The company is experiencing significant growth in neuro embolization, particularly from the new MMA embolization procedure, which is seen as a potential $1 billion opportunity.
- The STORM-PE study demonstrated that Penumbra's mechanical thrombectomy with CAVT is superior to anticoagulation for pulmonary embolism, showing extraordinary safety, significant RV/LV ratio reduction, and rapid procedure times. This data is influencing hospital protocols and expanding market penetration.
- Penumbra introduced 3.0, an enhanced thrombectomy product that offers faster operation and reduced blood loss, and is currently navigating the FDA review process for its Thunderbolt product, which is expected to have a higher average selling price.
Dec 3, 2025, 1:00 PM
Penumbra Discusses Q3 Performance, Product Innovations, and Market Opportunities
PEN
Product Launch
Revenue Acceleration/Inflection
New Projects/Investments
- Penumbra reported strong Q3 performance in its MO and access business, driven by the launch of Ruby XL and an expanded sales force.
- The company anticipates significant growth in its embolization franchise, particularly from MMA embolization, which is estimated to be a $1 billion opportunity.
- Positive results from the STORM-PE trial demonstrated that mechanical thrombectomy with CAVT is superior to anticoagulation for pulmonary embolism, with high safety and fast procedure times (25-minute device times, 56-minute procedure times). This data is expected to accelerate market penetration and change hospital protocols.
- Penumbra launched its 3.0 product, an upgrade to 2.0, which offers faster operation and reduced blood loss due to both software and hardware changes.
- The new neuro product, Thunderbolt, is currently under FDA review, with the company addressing clarifying questions, and is expected to have a higher average selling price (ASP) upon clearance.
Dec 3, 2025, 1:00 PM
Penumbra Reports Strong Q3 2025 Results and Raises Full-Year Revenue Guidance
PEN
Earnings
Guidance Update
Product Launch
- Penumbra generated total revenue of $354.7 million in Q3 2025, representing 17.8% year-over-year growth on a reported basis, and subsequently raised its full-year 2025 revenue guidance to $1,375 million-$1,380 million.
- The company achieved a gross margin of 67.8% in Q3 2025, an expansion of 130 basis points over the prior year, and reported operating income of $48.8 million, or 13.8% of revenue.
- U.S. revenue increased 21.5% year-over-year, driven by 18.5% growth in thrombectomy sales and 29.2% growth in embolization and access, with the latter benefiting from a new dedicated sales team and the RubyXL product launch.
- Penumbra received FDA clearance for Lightning Bolt 16 and Lightning Flash 3.0 and presented landmark results from the Storm PE trial, which demonstrated the superiority of CABT in reducing right heart strain with a comparable safety profile.
Nov 5, 2025, 9:30 PM
Quarterly earnings call transcripts for Penumbra.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more